The Japan Neuromyelitis Optica Spectrum Disorders/Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease Registry

Q4 Immunology and Microbiology

Clinical and Experimental Neuroimmunology Pub Date : 2025-08-30 DOI:10.1111/cen3.70023

Hideyuki Takeuchi, Yusei Miyazaki, Takao Kiriyama, Hikoaki Fukaura, Juichi Fujimori, Katsuhisa Masaki, Sonoko Misawa, Katsuichi Miyamoto, Nobuaki Yoshikura, Shoko Ukita, Kengo Nagashima, Ichiro Nakashima

{"title":"The Japan Neuromyelitis Optica Spectrum Disorders/Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease Registry","authors":"Hideyuki Takeuchi, Yusei Miyazaki, Takao Kiriyama, Hikoaki Fukaura, Juichi Fujimori, Katsuhisa Masaki, Sonoko Misawa, Katsuichi Miyamoto, Nobuaki Yoshikura, Shoko Ukita, Kengo Nagashima, Ichiro Nakashima","doi":"10.1111/cen3.70023","DOIUrl":null,"url":null,"abstract":"<div>\n \n <p>In Japan, five biologics (eculizumab, ravulizumab, satralizumab, inebilizumab, and rituximab) are currently available for treating neuromyelitis optica spectrum disorder (NMOSD). These biologics have dramatically suppressed the disease relapse rate; however, a big problem remains: there are no useful biomarkers or sufficient evidence in drug selection and drug switch for each patient. Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) has been recently identified, and its therapeutic strategy is still under investigation. To solve these problems, the Japan NMOSD/MOGAD Registry was launched in December 2023. In this paper, we summarize the current clinical problems of NMOSD and MOGAD in Japan and review the Japan NMOSD/MOGAD Registry project.</p>\n </div>","PeriodicalId":10193,"journal":{"name":"Clinical and Experimental Neuroimmunology","volume":"17 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical and Experimental Neuroimmunology","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/cen3.70023","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Immunology and Microbiology","Score":null,"Total":0}

引用次数: 0

Abstract

In Japan, five biologics (eculizumab, ravulizumab, satralizumab, inebilizumab, and rituximab) are currently available for treating neuromyelitis optica spectrum disorder (NMOSD). These biologics have dramatically suppressed the disease relapse rate; however, a big problem remains: there are no useful biomarkers or sufficient evidence in drug selection and drug switch for each patient. Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) has been recently identified, and its therapeutic strategy is still under investigation. To solve these problems, the Japan NMOSD/MOGAD Registry was launched in December 2023. In this paper, we summarize the current clinical problems of NMOSD and MOGAD in Japan and review the Japan NMOSD/MOGAD Registry project.

查看原文本刊更多论文

日本视神经脊髓炎频谱障碍/髓鞘少突胶质细胞糖蛋白抗体相关疾病登记

在日本，目前有5种生物制剂（eculizumab、ravulizumab、satralizumab、inebilizumab和rituximab）可用于治疗视神经脊髓炎谱系障碍（NMOSD）。这些生物制剂显著地抑制了疾病的复发率；然而，一个很大的问题仍然存在：在每个患者的药物选择和药物转换方面，没有有用的生物标志物或足够的证据。髓鞘少突胶质细胞糖蛋白抗体相关疾病（MOGAD）最近被发现，其治疗策略仍在研究中。为了解决这些问题，日本NMOSD/MOGAD登记处于2023年12月启动。本文总结了目前日本NMOSD和MOGAD的临床问题，并对日本NMOSD/MOGAD注册项目进行了回顾。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical and Experimental Neuroimmunology Immunology and Microbiology-Immunology and Microbiology (miscellaneous)

CiteScore

1.60

自引率

0.00%

发文量